• About WordPress
    • WordPress.org
    • Documentation
    • Learn WordPress
    • Support
    • Feedback
  • Log In
  • Request Membership
Skip to content
Medxy AI Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe
  • Home
  • Pancreatic Cancer
Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial
Posted inGeneral Surgery Oncology Specialties

Neoadjuvant FOLFIRINOX versus Gemcitabine-Based Chemoradiotherapy in Resectable and Borderline Resectable Pancreatic Cancer: Insights from the PREOPANC-2 Phase 3 Trial

Posted by By MedXY 10/15/2025
The PREOPANC-2 trial compared neoadjuvant FOLFIRINOX and gemcitabine-based chemoradiotherapy in resectable and borderline resectable pancreatic cancer, finding no significant overall survival difference between the two regimens.
Read More
Minimally Invasive Surgery for Left-Sided Pancreatic Cancer: Long-Term Safety Confirmed by DIPLOMA Trial
Posted inGeneral Surgery news Oncology

Minimally Invasive Surgery for Left-Sided Pancreatic Cancer: Long-Term Safety Confirmed by DIPLOMA Trial

Posted by By MedXY 10/09/2025
The DIPLOMA trial demonstrates that minimally invasive left pancreatectomy for resectable pancreatic cancer offers comparable long-term survival outcomes to open surgery, validating its oncologic safety and supporting its use in clinical practice.
Read More
Do Oily Fish Intake Increase Pancreatic Cancer Risk?
Posted inClinical Updates Family Medicine & Nutrition news Specialties

Do Oily Fish Intake Increase Pancreatic Cancer Risk?

Posted by By MedXY 09/25/2025
This Mendelian randomization study reveals a surprising association between higher oily fish consumption and increased pancreatic cancer risk, highlighting new directions for dietary guidance and pancreatic disease prevention.
Read More
Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial
Posted inGeneral Surgery Oncology Specialties

Chemoradiotherapy After Induction Chemotherapy: Enhancing R0 Resection Rates in Unresectable Pancreatic Cancer—Insights from the CONKO-007 Trial

Posted by By MedXY 09/10/2025
The CONKO-007 trial reveals that adding chemoradiotherapy after induction chemotherapy increases margin-negative (R0) resections in surgically treated unresectable pancreatic cancer but does not improve overall survival.
Read More
Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model
Posted inClinical Updates news Oncology Pathology & Lab Medicine

Revolutionizing Early Detection of Pancreatic Cancer: A cfDNA Fragmentomics and Machine Learning Model

Posted by By MedXY 09/08/2025
A new cell-free DNA fragmentomics model combined with machine learning achieves high accuracy for early pancreatic cancer detection, potentially improving patient outcomes through timely intervention.
Read More
Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention
Posted inMedical News news

Statins: Beyond Heart Health—A New Weapon Against Cancer Prevention

Posted by By MedXY 08/30/2025
Recent research uncovers that long-term statin use may prevent certain inflammation-driven cancers by blocking IL-33, heralding new possibilities in cancer prevention strategies.
Read More
Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk
Posted inMedical News news Oncology Specialties

Alcohol Intake and Pancreatic Cancer: New Global Data Clarifies the Risk

Posted by By MedXY 08/05/2025
A large pooled analysis across continents confirms a linear, dose-dependent association between alcohol consumption and pancreatic cancer risk—independent of smoking status and with significant public health implications.
Read More
Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial
Posted inClinical Updates news Oncology Specialties

Nab-Paclitaxel Plus Gemcitabine Outperforms mFOLFIRINOX and S-IROX as First-Line Therapy for Metastatic Pancreatic Cancer: Insights from the GENERATE (JCOG1611) Trial

Posted by By MedXY 08/01/2025
A large Japanese phase II/III trial shows nab-paclitaxel plus gemcitabine confers longer overall survival and better tolerability compared to mFOLFIRINOX and S-IROX in metastatic pancreatic cancer.
Read More
Alcohol and Pancreatic Cancer: Emerging Evidence of Risk
Posted innews Oncology Specialties

Alcohol and Pancreatic Cancer: Emerging Evidence of Risk

Posted by By MedXY 07/30/2025
New research strengthens the link between alcohol consumption and pancreatic cancer, highlighting both dose-dependent and threshold risks.
Read More
  • Group-Based Interventions to Reduce Gambling Involvement Among Male Football Fans
  • Is it safe to train children in soccer during the high temperatures of summer?
  • Cenegermin Eye Drops Show High Healing Rates in Chinese Patients with Moderate–Severe Neurotrophic Keratopathy
  • Outcomes of Maintenance Immunotherapy in Susac Syndrome
  • Brensocatib Shows Imaging Signals of Structural Benefit in Non‑CF Bronchiectasis: CT Substudy from ASPEN Suggests Reduced Mucus Plugging and Modest Airway Change
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

aging Alzheimer's disease artificial intelligence atrial fibrillation blood pressure breast cancer cardiovascular disease cardiovascular health cardiovascular risk chronic kidney disease clinical trial depression diabetes diet epidemiology exercise gut microbiota health heart failure Hypertension immunotherapy inflammation long-term outcomes MASLD mental health metformin Mortality multiple myeloma nutrition obesity older adults Physical Activity Pregnancy prevention prognosis public health randomized clinical trial randomized controlled trial randomized trial sexual health targeted therapy treatment type 2 diabetes weight loss women's health

Your health, we care

Copyright 2025 — Medxy AI. All rights reserved.
Scroll to Top
Sign in